Clinical trials: Light Chain (AL) Amyloidosis
AL Amyloidosis, Light Chain (AL) Amyloidosis
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality…
- Conditions
- AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
- Trial name
- NCT05486481
- Testing
- Venetoclax, Dexamethasone, Daratumumab
- Sponsor
- Alfred Chung, MD
Systemic Amyloidosis
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis.
- Trial name
- NCT06342466
- Testing
- Bortezomib, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jin Lu, MD
Amyloidosis
Body Composition in Systemic Amyloidosis
Malnutrition is a prominent clinical feature of patients affected by systemic immunoglobulin light-chain amyloidosis (AL), with a prevalence ranging between 25-50%.
- Trial name
- BIVAmyloid (NCT02111538)
- Testing
- Dietary advice
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
AL Amyloidosis
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
The goal of this clinical trial is to evaluate the effectiveness and safety of CM-336, which is a BCMA/CD3 BiTE, in patients with relapsed/refractory AL amyloidosis or newly diagnosed AL amyloidosis with insufficient depth of…
- Trial name
- NCT06769555
- Testing
- CM-336 BCMA/CD3 bispecific antibody
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Systemic Amyloidosis
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
This is a single-center, exploratory, Phase 1 Positron Emission Tomography/x-ray Computed Tomography (PET/CT) imaging study to detect amyloidosis that will enroll patients with a confirmed diagnosis of systemic amyloidosis.
- Trial name
- NCT03678259
- Testing
- 124I-p5+14 Injection
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Light Chain (AL) Amyloidosis
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic…
- Trial name
- NCT06629818
- Testing
- Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous), Venetoclax, Dexamethasone
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital